Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 1633.7× sales vs its 997.9× historical median P/S.
Fair value ≈ $0.00 · price $0.00 today
Overvalued · 64% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ITNS
AI View of Licensing deal with Caring Brands
Sales of the over-the-counter (OTC) nausea relief product Emesyl are managed by Caring Brands Inc.. Caring Brands recently secured an exclusive global license to manufacture, market, and distribute the product, which was previously owned by Itonis Inc..
Current Status of Emesyl Sales
License Agreement: As of early January 2026, Caring Brands has the sole worldwide rights to the product.
Commercialization Plan: Caring Brands is assuming responsibility for the entire sales strategy, including manufacturing, marketing, and global distribution.
Market Opportunity: The company sees a significant market opportunity, citing a projected global nausea treatment market value exceeding $6.23 billion in 2025.
Sales Launch: The news articles indicate that the company plans to "revitalize and scale Emesyl's market presence" and are expected to launch a total of five products over the next two years.
$ITNS An investor has to love this headline!
https://www.theglobeandmail.com/investing/markets/markets-news
$6.23 Billion Market Opportunity Via Exclusive Global License to Manufacture and Sell Emesyl OTC Nausea Relief Product by Caring Brands Inc. (Nasdaq: CABR)
$ITNS LICENSING DEAL JUST ANNOUNCED!
Well, they just may have something happening.....FINALLY!
https://www.tradingview.com/news/tradingview:ede01069177b1:0-caring-brands-signs-license-agreement-with-itonis-
$ITNS AR is out and contains the same
In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl®
product. We had expected to gather feedback with performance metrics via an online
dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it
being “Homeopathic” and the “only fast acting nasal spray” on the market.
Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl®
nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor.
The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line
within its wholly-owned subsidiary, Itonis Holdings, Inc.
On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in
exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock.
